Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
P/B ratio for Iovance Biotherapeutics, Inc. (IOVA)
P/B ratio as of 2023: 3.27
According to Iovance Biotherapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.27. At the end of 2022 the company had a P/B ratio of 2.04.
P/B ratio history for Iovance Biotherapeutics, Inc. from 2008 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.27 |
| 2022 | 2.04 |
| 2021 | 4.71 |
| 2020 | 9.77 |
| 2019 | 11.51 |
| 2018 | 1.85 |
| 2017 | 3.59 |
| 2016 | 2.30 |
| 2015 | 3.30 |
| 2014 | 4.38 |
| 2013 | 5.82 |
| 2012 | -1.55 |
| 2011 | -5.94 |
| 2010 | 127.82 |
| 2009 | -3107.21 |
| 2008 | 58486.87 |